AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00898716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807
Description: Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
Study NCT01298791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting
Description: Providers will sit during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain seated while communicating with the patient and caregiver.
Study NCT01298791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing
Description: Providers will stand during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain standing while communicating with the patient and caregiver.
Study NCT02937246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEMS(self-expandable metallic stent)
Description: Find the obstruction site by ERCP(endoscopic retrograde cholangiopancreatography) and insertion the SEMS(self-expandable metallic stent) through duodenal endoscopy. Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
Study NCT02937246 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting by ERCP (endoscopic retrograde cholangiopancreatography)
Study NCT01054729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir tablet(s) administered orally once daily
Study NCT01054729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match sofosbuvir administered orally once daily
Study NCT01054729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
Study NCT01054729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
Study NCT01054729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Study NCT01054729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Study NCT00954369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]W372
Description: The individual doses of \[F-18\]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging.
Study NCT00224198 — intervention group
Intervention type: PROCEDURE
Intervention: Lung Disease
Description: Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. In the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways.In the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently to obtain epithelial cells lining the airway. Certain individuals may have bronchial wall biopsy carried out. In this procedure, a small biopsy forceps is passed through the bronchoscope and a small biopsy is obtained from the bronchial wall.
Study NCT03809858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Klue App
Description: The Klue App utilizes an Apple Watch to detect eating or drinking behavior. The App can initiate a sequence of questions when eating/drinking is detected to determine if a subject has administered a bolus for the meal or if they need to do so.
Study NCT03663413 — intervention group
Intervention type: DEVICE
Intervention: non-invasive monitor
Description: cutaneous EEG monitor
Study NCT02581137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02581137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO
Study NCT01239225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal ultra-sound
Study NCT01239225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound
Study NCT01125735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIST Therapy
Description: The MIST Therapy System is designed to deliver therapeutic ultrasound to the wound bed without direct contact of the device to the body (noncontact). The system generates and propels the therapeutic MIST Therapy towards the tissue. The saline solution is directed to the tip surface and is atomized through the vibration of the tip surface. This surface creates atomization of the fluid, breaking it apart into small particles of uniform size. Once the particles of fluid are released from the tip, a second phenomenon, the acoustic pressure wave, drives them toward the wound.
Study NCT01125735 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
Study NCT02775123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosorb
Description: A cytoadsorbent cardridge (Cytosorb) will be added to the extra-corporeal circuit (CPB).
Study NCT04750447 — intervention group
Intervention type: DEVICE
Intervention: XEN 63
Description: The Xen gelatin microstent (Allergan, CA, USA) is a 6mm gelatin tube used in microinvasive glaucoma surgery (MIGS) to create a bleb. A bleb is a fluid filled blister located in the tissue covering the white portion of the eye (the conjunctiva) created after glaucoma surgery. The bleb allows the eye pressure (intraocular pressure - IOP) to be lowered by bypassing the natural pathways by which the fluid called aqueous leaves the eye and redirecting it towards the bleb to be absorbed by other pathways. Amongst the main advantages of this device is the ability to create a bleb without disrupting tissue unlike other methods of glaucoma surgery (e.g., trabeculectomy). This decreases the amount of wound healing and scarring, and potentially limiting bleb failure.
Study NCT00847847 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anconeus Muscle biopsy
Description: Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.
Study NCT02416973 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Provant
Study NCT03752164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga and Mindfulness Skills
Description: Single brief session in which children are taught yoga and skills in mindfulness
Study NCT03869411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supervised aerobic exercise or home-based aerobic exercise
Description: The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation.
Study NCT03869411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: supervised aerobic exercise or home-based aerobic exercise
Description: The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation.
Study NCT00005843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Study NCT04193813 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational study
Study NCT02121145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vivotif
Description: 3 oral doses
Study NCT02059031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 Reference formulation
Description: GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water
Study NCT02059031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 New formulation 1
Description: GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water
Study NCT02059031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 New formulation 2
Description: GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
Study NCT02121145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typherix
Description: one intramuscular dose
Study NCT01459276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FAB-6011
Description: One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
Study NCT01459276 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with FluvalAB
Description: One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
Study NCT01242488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
Study NCT01242488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 120 mg sc at Weeks 0, 2, 4 6, 8, and 10
Study NCT01242488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 240 mg sc at Weeks 0, 2, 4 6, 8, and 10
Study NCT01242488 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab (Actemra or RoActemra)
Description: 8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
Study NCT01242488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 60 mg sc at Weeks 0, 4 and 8
Study NCT01242488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 240 mg sc at Weeks 0, 4 and 8
Study NCT01242488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 120 mg sc at Weeks 0, 4 and 8
Study NCT01242488 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sc
Description: 0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
Study NCT01242488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo sc
Description: 0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
Study NCT01242488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo sc
Description: 0.9% Sodium chloride for injection at Weeks 2, 6 and 10
Study NCT01242488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo iv
Description: 0.9% Sodium chloride for injection at Weeks 0, 4 and 8
Study NCT04473729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiovisual speech training in noise for children
Description: Children will participate in listening training in the form of an iPad app
Study NCT01242488 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo iv
Description: 0.9% Sodium chloride for injection at Weeks 0, 4 and 8
Study NCT02995668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength-Function
Description: Preoperative functional and strength capabilities training.
Study NCT02995668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength-Function
Description: Preoperative functional and strength capabilities training.
Study NCT02995668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance-Proprioception
Description: Preoperative proprioceptive and balance capabilities training
Study NCT01518205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LDL-apheresis
Description: The patient of the Arm LDL-apheresis in addition to standard therapy, will undergo a cycle of LDL-apheresis.~LDL-apheresis will be performed with B.Braun Avitum H.E.L.P. System. Apheretic treatment scheme: 10 apheretic sessions carried out as follows: the first 2 with a 3 day distance (i.e. 2 treatments in one week), successively 1 session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used.
Study NCT05029648 — intervention group
Intervention type: OTHER
Intervention: Cohort
Description: Cohort
Study NCT05170698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coaltion excision and arthroereisis
Description: Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
Study NCT05170698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coalition excision and corrective osteotomies
Description: Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
Study NCT04121598 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
Study NCT00365469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]
Study NCT00365469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available cow's milk based infant formula without probiotic supplementation
Study NCT02269007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated quadrivalent influenza vaccine (split virion)
Description: 0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
Study NCT01158976 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexanoic Acid
Description: 450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
Study NCT01158976 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: soybean oils with strawberry flavoring
Study NCT01461148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSP peptides
Description: 100 ug of each FSP (TAF1B(-1), HT001(-1) and AIM2(-1), weekly for 4 consecutive weeks and repeated every four weeks up to a total of 3 cycles.
Study NCT02336698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
Study NCT01513850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepabulin IV
Description: I.V.
Study NCT01391377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin/Laropiprant combination
Description: Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
Study NCT01391377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Placebo
Study NCT02796326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: improved tracheal balloon dilatation
Description: Treatment for laryngotracheal stenosis using a modified tracheal dilatation balloon
Study NCT00723775 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK706769 & KALETRA
Description: GSK706769 alone and GSK706769 + Kaletra
Study NCT02973958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: See active comparator description
Study NCT02973958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: See active comparator description
Study NCT02973958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: See active comparator description
Study NCT02973958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: See active comparator description
Study NCT02973958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: See active comparator description
Study NCT02973958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: See active comparator description
Study NCT02973958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: See active comparator description
Study NCT02973958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: See active comparator description
Study NCT02973958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: See experimental arm description
Study NCT03210506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
Study NCT05588518 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: desensitizing agents -10% Propolis
Description: 10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives.
Study NCT05588518 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: desensitizing agents -10% Propolis
Description: 10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives.
Study NCT02835534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTNK-tPA
Description: Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
Study NCT02835534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alteplase
Description: Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
Study NCT02073513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape plus thenar pressure (PPTG)
Description: In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied to control the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions.
Study NCT02073513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taping Group (TG)
Description: In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
Study NCT02336698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 1 mg
Description: Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
Study NCT02336698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 3 mg
Description: Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
Study NCT03913364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: B. bifidum 900791-containing ice cream
Study NCT03913364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ice-cream